-+ 0.00%
-+ 0.00%
-+ 0.00%

Jaguar Health Completes Its Ongoing Effectiveness Study Of Crofelemer Delayed-Release Tablets For Chemotherapy-Induced Diarrhea In Dogs

Benzinga·04/08/2026 12:36:26
Listen to the news
  • Crofelemer, under the name Canalevia-CA1, is currently conditionally approved for the sole indication of treating CID in dogs. The approval for Canalevia CA-1 will expire on December 21, 2026. In the second quarter of 2026 Jaguar plans to submit and file the results of the company's effectiveness study and the positive results of a study of crofelemer delayed-release tablets for treatment of CTD in dogs receiving neratinib - a targeted tyrosine kinase inhibitor (TKI) chemotherapy agent.